Trial data suggest beneficial class effects of SGLT2 inhibitors, including dapagliflozinJuly 17, 2018Diabetes
CVD-REAL 2: Lower mortality, CV risks with SGLT-2i vs. DPP-4i treatment in T2DMJuly 17, 2018DiabetesCarotid Disease & Stroke
